Pharma execs raise concerns about Trump’s plans for the FDA; Merck ends study of experimental Alzheimer’s drug; Amgen seeks new indication for Blincyto
Last week President Trump told drugmakers that ‘the pricing has been astronomical.’
It’s hard to be against the concept of reform, but Trump is better known for epithets than policy details, Kamp writes.
A new survey found that 34% of healthcare and pharma marketers say that the election of President Trump will not affect their marketing budgets.
A Haymarket Media survey of more than 700 client-side marcomms execs in the US reveals the shift in power will not significantly affect budgets.
MM+M is proud to announce the fourth annual Pinnacle Awards program, which celebrates the medical marketing industry’s most venerable marketers, strategists and creators.
Get the most out of
Register for free and enjoy unlimited access to: